Cold Agglutinin Disease Foundation

Cold Agglutinin Disease FoundationCold Agglutinin Disease FoundationCold Agglutinin Disease Foundation
  • Home
  • About Us
  • CAD & Treatments
  • Latest News & Events
  • Clinical Trials
  • Resources
  • Register Web Series
  • Our Stories
  • NewsLetter
  • Stay In The Know
  • Share Your Story
  • Contact Us
  • Donation
  • Privacy & Policies
    • Home
    • About Us
    • CAD & Treatments
    • Latest News & Events
    • Clinical Trials
    • Resources
    • Register Web Series
    • Our Stories
    • NewsLetter
    • Stay In The Know
    • Share Your Story
    • Contact Us
    • Donation
    • Privacy & Policies

Cold Agglutinin Disease Foundation

Cold Agglutinin Disease FoundationCold Agglutinin Disease FoundationCold Agglutinin Disease Foundation
  • Home
  • About Us
  • CAD & Treatments
  • Latest News & Events
  • Clinical Trials
  • Resources
  • Register Web Series
  • Our Stories
  • NewsLetter
  • Stay In The Know
  • Share Your Story
  • Contact Us
  • Donation
  • Privacy & Policies

clinical trials

BIVV009-01 - Safety, Tolerability and Activity of BBIVV009 in Healthy Volunteers and Patients with Complement Mediated Disorders (BIVV009-01) Phase 1 Sanofi (Bioverativ) and Collaborators

http://clinicaltrials.gov/ct12/show/NCT02502903

Recruiting Last Updated Post December 18, 2019

Estimated Completion Date March 2021


BIVV020 - A Safety and Tolerability Study of BIVV020 in Adults with Cold Agglutinin Disease Phase 1 Sanofi Genzyme

https://clinicaltrials.gov/ct2/show/NCT04269551 

Recruiting 

Estimated Completion Date November 2021


 BIVV009 - (Sutimlimab - press release May 14, 2020 ) A Study to Assess the Efficacy and safety of BIVV009 in Participants With Primary Cold Agglutinin Diseases Without A Recent History of Blood transfusion (Cadenza Study)  Phase 3  Sanofi Genzyme
https://clinicaltrials.gov/ct2/show/NCT03347422
Active, Not Recruiting
Estimated Completion Date December 2021 

image1616

We are writing to introduce ourselves and to share some exciting cold agglutinin disease (CAD) news. 


Apellis is a development stage, global biopharmaceutical company that was established 10 years ago to combine courageous science, creativity, and compassion to deliver life-changing medicines for a broad range of serious diseases.  


Read Here for More:

image1617

APL-2 - Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 (Pegcetacoplan) in Patients With wAIHA or CAD (Plaudit Study) Phase 2 


Apellis Pharmaceuticals https://clinicaltrials.gov/ct2/show/NCT04269551

Active, Not Recruiting Last Updated Post February 7, 2020 

Estimated Completion Date December 2020

image1618

Ascend-Waiha

The purpose of the current study is to assess the efficacy and safety/tolerability of two dose regimens of RVT-1401 (currently known as IMVT-1401) in the treatment of patients who have failed or not tolerated at least one prior treatment for WAIHA. In addition, the study is designed to characterize the effect of RVT-1401 exposure on reduction in IgG and other exploratory biomarkers.


https://ascendwaihastudy.com/ and the trial video below.

image1619

Immunovant Ascend - Waiha Study Video

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. The safety and scientific validity of these studies is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the CADF Foundation. Please review our Privacy and Policies for more information. 

Copyright © 2020 Cold Agglutinin Disease Foundation - All Rights Reserved.

Privacy & Policies

Contact Us: info@cadfadvocacy.org

ZOOM Webinars

Register for our CAD Foundation Summit Series for 2021 and join us online!

Register Here